Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sensei Biotherapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SNSE
Nasdaq
8731
https://www.senseibio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sensei Biotherapeutics Inc
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
- Apr 24th, 2024 8:05 pm
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
- Apr 9th, 2024 11:30 am
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
- Apr 4th, 2024 8:05 pm
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
- Mar 22nd, 2024 11:30 am
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
- Mar 6th, 2024 12:30 pm
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Feb 28th, 2024 12:30 pm
Sensei Biotherapeutics to Present at Upcoming Conferences
- Feb 7th, 2024 12:30 pm
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Jan 4th, 2024 12:30 pm
Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results
- Nov 7th, 2023 1:09 pm
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Nov 7th, 2023 12:30 pm
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
- Nov 3rd, 2023 8:05 pm
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
- Nov 1st, 2023 11:30 am
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
- Oct 25th, 2023 1:05 pm
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
- Oct 23rd, 2023 11:30 am
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
- Sep 27th, 2023 11:30 am
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- Sep 21st, 2023 11:30 am
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- Sep 13th, 2023 11:30 am
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
- Aug 30th, 2023 4:32 pm
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
- Aug 30th, 2023 11:30 am
Billionaire Stan Druckenmiller’s Small-Cap Stock Picks
- Aug 19th, 2023 2:44 pm
Scroll